Open an account

Indaptus Therapeutics

INDP · NASDAQ

$2.96+$0.23 (+8.42%)TodayMarket closed ·
Prev close $2.73

INDP analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Dec 7, 2024

Bull case

Indaptus Therapeutics Inc. has made significant advancements with its pre-clinical candidate, Decoy20, which has shown promising safety and efficacy profiles in its Phase 1 clinical trial, particularly for hard-to-treat cancers such as colorectal and pancreatic carcinoma. The favorable safety data, characterized by manageable side effects and rapid clearance of the drug from the bloodstream, further consolidates the company's innovative "pulse-prime" immunotherapy strategy aimed at activating the immune system efficiently. Additionally, the narrower than expected net loss of $0.45 per share for Q1 2024 indicates sound financial management and supports a positive outlook for future developments as the clinical trial proceeds to assess multiple dosing regimens.

Bear case

Indaptus Therapeutics is projected to incur a net loss of $1.72 per share for the full year 2024, driven by risks such as slower trial enrollment, potential negative trial outcomes, adverse regulatory decisions, and diluted market uptake. The company has reported a decrease in research and development spending, totaling $1.6 million compared to the anticipated $2.1 million, alongside lower general and administrative expenses of $2.4 million, which slightly adjusted their earlier net loss estimate for 2024. The sustained projection of a net loss of $1.44 per share for 2025 further emphasizes ongoing financial challenges and reinforces a negative outlook for the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.